BIOINVEST BREAKING NEWS â The Medicines Company (MDCO) â Inclisiran FDA Path Clear After End of Phase II Meeting â Lower Risk, Value Enhanced â The Medicines Company announced that the primary endpoint of the Phase III registrational trial will be LDL-C levels. This is a major positive for MDCO â significantly reduces the risk and increases the value of Inclisiran.